MINIMUM FOREARM VASCULAR RESISTANCE IN ESSENTIAL HYPERTENSION AFTER ANTIHYPERTENSIVE THERAPY

DUŠEK J.¹, SIEGELOVÁ J.¹ FIŠER B.², SAVIN E.³, MARTINEAUD J.P.¹

¹Department of Functional Diagnostics and Rehabilitation, ²Department of Physiology, Faculty of Medicine, Masaryk University, Brno
³Faculty of Medicine Lariboisière, Paris, France

Abstract

The aim of the present study was to analyse the relationship between the blood pressure decrease and minimum forearm vascular resistance decrease due to different anti-hypertensive therapies. Patients with mild to moderate essential hypertension (n=40) were examined after placebo therapy and 3 months after the following therapy with Ca antagonists verapamil (n=10), nitrendipine (n=10), diltiazem (n=10), and with the ACE inhibitor enalapril (n=10). From our results we conclude that anti-hypertensive therapy with all Ca antagonists and the ACE inhibitor decreased the minimum forearm vascular resistance. No differences among these drugs were observed.

Key words
Minimum forearm vascular resistance, Essential hypertension, Antihypertensive therapy, Ca antagonists, ACE inhibitor

INTRODUCTION

Vascular hypertrophy, which is inferred from an increase in minimum forearm vascular resistance (FVRₘᵢₙ), is present in patients with essential hypertension without therapy (1). The development of structural changes in the systemic arteries and arterioles contributes to the continuation and progressive worsening of arterial hypertension (2). The aim of the present study was to analyse the relationship between blood pressure (BP) decrease and (FVRₘᵢₙ) decrease due to a range of different antihypertensive therapies.

MATERIALS AND METHODS

The study was carried out on 40 male patients (age, 48±5 years; height, 181±5cm; weight, 86±8kg) with mild to moderate essential hypertension who had been treated with placebo therapy followed by administration of different anti-hypertensive drugs for 3 months. According to the medication used, the patients were distributed into four groups, three received Ca antagonists and the fourth an angiotensin-converting enzyme (ACE) inhibitor. Group EH V (n=10) received
verapamil at a single morning dose of 240 mg (slow releasing) every day; group EH N (n=10) was
given nitrendipine at a dose of 20 mg twice a day; group EH D (n=10) was treated with dilthiazem
at a dose of 90 mg (retard) twice a day. Group EH E (n=10) received enalapril at a single daily dose
of 13.3±2.1mg.

Medical tests and examinations excluded any other disease and the diagnosis of essential
hypertension was made according to the WHO criteria to rule out any form of secondary
hypertension. All patients had been followed up at the clinic at least 3 years prior to this study.

We measured blood pressure and the maximum forearm blood flow after occlusion
plethysmography (5 min; occlusion pressure, 300 mmHg) using a Fluoscript device. The forearm blood
flow was measured and expressed in ml per 100 ml of tissue per min. The minimum forearm vascular
resistance (FVRmin) was calculated from the mean arterial blood pressure value (MAP, mmHg) divided
by the maximum forearm blood flow. These tests were carried out on 40 patients at the end of placebo
treatment and on each of the four groups after 3 months of anti-hypertensive treatment.

The results were calculated as mean±SD for the four groups during the placebo phase. The
statistical significance of differences between the placebo and treatment stages in each group was
determined by the Wilcoxon test for paired data.

The study was approved by the Ethics Committee of the Masaryk University Teaching Hospital.

RESULTS

The following results are presented in Table 1 and Fig. 1: FVRmin
(mmHg/ ml per 100 ml per min; mean±SD) and BP (MAP, mmHg;
mean±SD) in each treated group during the placebo therapy phase; the
decrease due to the therapy in MAP and FVRmin (dP and dR, expressed as
percentages) and the dP/dR ratio.

On the basis of our results we conclude that anti-hypertensive therapy
with different Ca antagonists or with an ACE inhibitor decreased the
minimum forearm vascular resistance. There were no observed differences
associated with these drugs.

DISCUSSION

In the pathogenesis of essential hypertension, elevated blood pressure is
connected with increased peripheral resistance. Many recent studies have
shown that ACE inhibitors are very effective in preventing or inhibiting
many of the morphological and functional changes associated with
hypertension that take place in the media as well as in the endothelium of
arteries and arterioles (3). In a clinical study, it has been shown that long-last-
ing treatment with ACE inhibitors induced relaxation in arterial smooth
muscles and, therefore, an increase in arterial diameter and compliance in
hypertensive patients. These vascular protective effects seem to be at least
partly independent of the anti-hypertensive effect of these drugs since, in
many cases, pure vasodilatators do not have similar effects (4,5). Radial
artery compliance–pressure curves were not changed by placebo, atenolol
or nitrendipine treatment, but they were changed in subjects treated by
lisinopril, an ACE inhibitor (6).
Table 1

The results of FVR_{min} (in mmHg/ ml per 100 ml per min) and the mean BP (MAP, mmHg) in the four groups after the therapy, and a decrease in MAP (dP,\%), a decrease in FVR_{min} (dR,\%) and the dP/dR ratio

<table>
<thead>
<tr>
<th></th>
<th>EH V</th>
<th>EH N</th>
<th>EH D</th>
<th>EH E</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVR_{min}</td>
<td>4.7±1.6</td>
<td>6.6±1.5</td>
<td>4.1±1.5</td>
<td>4.6±1.5</td>
</tr>
<tr>
<td>MAP</td>
<td>118.8±7.1</td>
<td>115.7±5.6</td>
<td>121.1±9.1</td>
<td>109.7±8.7</td>
</tr>
<tr>
<td>dP</td>
<td>*12.4±7.1</td>
<td>*13.7±6.5</td>
<td>*17.5±7.9</td>
<td>*10.4±6.9</td>
</tr>
<tr>
<td>dR</td>
<td>*32.6±8.6</td>
<td>*36.2±7.6</td>
<td>*44.5±5.2</td>
<td>*41.1±15.3</td>
</tr>
<tr>
<td>dR/dP</td>
<td>2.6±1.4</td>
<td>2.6±0.5</td>
<td>2.5±0.9</td>
<td>4.1±1.6</td>
</tr>
</tbody>
</table>

FVR_{min}, minimum forearm vascular resistance; BP, blood pressure; MAP, mean arterial pressure; *, P<0.05 (statistical significance of differences between the groups in the treatment versus the placebo phases).

Fig. 1

Relationship between the decrease in mean blood pressure (MAP \%) and the decrease in forearm vascular resistance (FVR_{min} \%) caused by the antihypertensive treatment by verapamil (EH V), nitrendipine (EH N), diltiazem (EH D) and enalapril (EH E).
Our previous results (7) as well as the results from the present study did not confirm these conclusions completely. The findings of the present study showed that the FVR$_{\text{min}}$ decreasing effect is not greater after ACE-inhibitor treatment than that after verapamil, nitrendipine and dilthiazem and also that Ca-antagonists, themselves, are very effective in remodeling of resistance vessels.

In agreement with our results, there are also the results from a clinical study by Rossi et al. (1). These authors prospectively investigated the relationship of plasma renin activity and aldosterone levels to carotid artery lesions in essential hypertension. They have found that primary hypertensive patients have a prevalence and severity of carotid artery lesions higher than normotensive subjects. The maximal degree of stenosis was more strongly predicted by pulse pressure and the known duration of hypertension. Their findings do not support the hypothesis that a high renin-sodium profile carries an excess risk of carotid artery lesion in primary hypertensives.

REFERENCES